New gonadotropin-releasing hormone glycolipids with direct antiproliferative activity and gonadotropin-releasing potency by Varamini, Pegah et al.
Accepted Manuscript
Title: New Gonadotropin-releasing Hormone Glycolipids with
Direct Antiproliferative Activity and Gonadotropin-Releasing
Potency
Authors: Pegah Varamini, Friederike M. Mansfeld, Ashwini
Kumar Giddam, Frederik Steyn, Istvan Toth
PII: S0378-5173(17)30144-8
DOI: http://dx.doi.org/doi:10.1016/j.ijpharm.2017.02.054
Reference: IJP 16458
To appear in: International Journal of Pharmaceutics
Received date: 13-10-2016
Revised date: 10-2-2017
Accepted date: 19-2-2017
Please cite this article as: Varamini, Pegah, Mansfeld, Friederike M.,
Giddam, Ashwini Kumar, Steyn, Frederik, Toth, Istvan, New Gonadotropin-
releasing Hormone Glycolipids with Direct Antiproliferative Activity and
Gonadotropin-Releasing Potency.International Journal of Pharmaceutics
http://dx.doi.org/10.1016/j.ijpharm.2017.02.054
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
  1 
New Gonadotropin-releasing Hormone Glycolipids with Direct Antiproliferative Activity and Gonadotropin-
Releasing Potency  
Pegah Varaminia,1*, Friederike M. Mansfelda,2, Ashwini Kumar Giddama, Frederik Steynb, Istvan Totha,c,d 
 
aSchool of Chemistry and Molecular Biosciences, The University of Queensland, Briasbane, Australia, bThe 
University of Queensland Centre for Clinical Research and the School of Biomedical Sciences, Briasbane, 
Australia cSchool of Pharmacy, The University of Queensland, Briasbane, Australia. dInstitute for Molecular 
Biosciences, The University of Queensland, Brisbane, Australia. 
Graphical abstract 
 
 
 
 
 
 
Gonadotropin-releasing hormone (GnRH) is an endogenous peptide with a short biological half-life. 
Although GnRH analogs (eg. triptorelin) are developed with enhanced stability compared to the 
native peptide, they still suffer from poor biological stability and pharmacokinetic properties. 
Furthermore, they are only effective in the treatment of hormone-dependent reproductive cancers. In 
this study we applied lipidation and glycosylation along with D-amino acid substitution at position 6 
(D-Trp6) to improve the stability, permeability, and consequently the potency of the GnRH peptide 
and triptorelin. We showed that the conjugation of GnRH with a lipid moiety and carbohydrates made 
all modified constructs (1-8) more stable than the parent peptide against enzymatic degradation (5.5 
to 6.5 times). Two of the lactose-modified glycolipopeptides, 3 and 6, showed 27 and 16 times higher 
membrane permeability than the parent GnRH, respectively. All analogs with D-Trp6-substitution (4-
6) exerted GnRH receptor-mediated antiproliferative activity in prostate and ovarian GnRH-receptor 
positive cell lines. They were more potent than triptorelin in the hormone-independent prostate cancer 
cell line: DU145. Compound 6 (lactose-modified) was the most potent analog for stimulating the 
release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) gonadotropins from rat 
pituitary cells in vitro. The same glycolipopeptide exhibited a higher efficacy and duration of action 
in stimulating the release of LH than triptorelin in a preclinical mouse model. The superior activity 
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of lipid- and carbohydrate-substituted triptorelin analog 6 made it a promising candidate for the 
development of new GnRH agonists to treat both hormone-dependent and hormone-refractory 
prostate cancer. 
.LIST OF ABBREVIATIONS 
°C: degrees Celsius, ANOVA: Analysis of variance, AUC: Area under the curve, BBB: Blood brain barrier, Boc: tert-
Butyloxycarbonyl, C12: 2-amino-D,L-dodecanoic acid, CSS: Charcoal stripped serum, DHT: Dihydrotestosterone, DMEM: 
Dulbecco's modified Eagle's medium, DMSO: Dimethyl sulfoxide, E2: 17ß-estradiol, FBS: Fetal bovine serum, FSH: Follicle-
Stimulating Hormone, Gal: Galactose, Glc: Glucose, GnRH: Gonadotropin-Releasing Hormone, HPLC: High performance 
liquid chromatography, HR-MS: High resolution mass spectrometry, Lac: Lactose, LC-MS: Liquid Chromatography-Mass 
Spectrometry, LH: Luteinising-Hormone, MTT: (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), Papp: 
Apparent permeability, PBMC: Peripheral blood mononuclear cell, PBS: Phosphate-buffered saline, RP-HPLC: Reverse-phase-
high performance liquid chromatography, Rt: Retention time, t1/2: half-life 
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1. INTRODUCTION 
 Gonadotropin-releasing hormone (GnRH) is a short-acting decapeptide with a biological half-life of less than 30 
min (Chan and Nerenberg, 1987). It is secreted by the hypothalamus and stimulates the release of LH and FSH from 
the anterior pituitary gland. Structural modification of GnRH has resulted in analogs with higher receptor affinity and 
improved proteolytic stability than native GnRH. These agonists (e.g. triptorelin, buserelin, goserelin and leuprolide) 
are currently in clinical use (Berger et al., 1991). Continuous administration of GnRH agonists leads to a sustained 
GnRH receptor occupancy and desensitization of GnRH receptors in the pituitary, leading to medical castration 
(Pawson et al., 2008). Hormonal castration via the GnRH receptor is a well-established strategy for the treatment of 
hormone-dependent cancers of prostate, breast, ovarian and endometrial tissues (Schally et al., 1984). 
A direct anticancer activity has also been reported for the GnRH analogs (Marelli et al., 2007). GnRH receptors are 
overexpressed both in reproductive organ cancers and cancers unrelated to the reproductive system (Franklin et al., 
2003). GnRH analogs exert specific GnRH receptor-mediated antiproliferative, antimitogenic, and antimetastatic 
activities on cancer cells (Marelli et al., 2007). A direct relationship has been found between this effect of GnRH 
agonists and the level of GnRH receptor expression in the particular cell line.(Morgan et al., 2008) 
Modifications that retard the dissociation rate of the GnRH analog from its receptor have been shown to increase its 
biopotency and bioavailability in vivo, which are highly dependent on the peptide’s stability and permeability across 
biological membranes. In spite of extensive research in the field of hormonal therapy and development of various 
GnRH agonists over the past three decades, GnRH peptide analogs still suffer from poor pharmacokinetic properties. 
Depot formulations that are injected subcutaneously are also available; however, they can lead to several side effects 
such as leukocytoblastic vasculitis (Turk et al., 2007) and injection-site granulomas (Shiota et al., 2007). 
Subcutaneous implants have also been developed. Implants require a surgical incision and cause even more significant 
reactions at the administration site than depot formulations (Abouelfadel and Crawford, 2008). Hence, development 
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of a more stable GnRH agonist with improved pharmacokinetics that allows for less frequent administration is highly 
desirable. Different strategies have been investigated for the effective delivery of GnRH agonists to enhance stability 
and improve their transport profile in biological systems (Mezo et al., 2008). 
Several chemical modifications have been applied to improve the biological and physicochemical properties of 
peptides. Conjugation to carbohydrates has been shown to considerably enhance peptide stability, permeation across 
biological membranes, and bioavailability (Egleton and Davis, 2005; Varamini et al., 2012b). Lipidation increases 
the lipophilicity and membrane-like properties of the peptides, thus facilitates their penetration across biological 
barriers (Griffin, 2011). Lipoamino acids are α-amino acids with alkyl side chains of varying length (usually C8-20). 
Their similarity to α-amino acids allows facile incorporation into the structure of peptides (Toth, 1994). Lipoamino 
acids were shown to be cleaved from their parent peptides in vitro (Blanchfield et al., 2005) thus can be incorporated 
into peptide sequences do develop a more lipophilic prodrug. Use of both lipidation and glycosylation will confer a 
balance between the lipophilic and hydrophilic characteristics. This may result in higher potency by improving peptide 
stability against enzymatic hydrolysis and permeability through biological membranes (Drouillat et al., 1998; Koda 
et al., 2008; Nomoto et al., 1998). 
Tyr5-Gly6 and Pro9-Gly10 bonds, and to a lesser extent, the pGlu1-His2 and Gly6-Leu7 bonds are known as the main 
cleavage sites of GnRH (Griffiths and Mcdermott, 1983). Therefore, due to their susceptibility, these bonds are the 
most common modification sites to stabilize the GnRH peptide. The majority of clinically used GnRH agonists 
(including triptorelin), contain a D-amino in place of glycine at position 6 (Beyer et al., 2011). This replacement leads 
to a greater metabolic stability of the compound (Karten and Rivier, 1986). Furthermore, the D-amino acid in this 
position enhances receptor binding by stabilizing the type II ß-turn conformation that has been shown to be important 
for interaction with the receptor (Laimou et al., 2010). Thus the GnRH agonists with D-amino acid modification at 
position 6 were more potent than the GnRH peptide itself. There are also reports on the development of active agonists 
by D-amino acid substitutions at position 7 (Ling and Vale, 1975).  
In this study we applied a combination of glycosylation, lipidation and D-amino acid substitution strategies to improve 
the stability and potency of the GnRH peptide. We hypothesized that increased stability and potency would lead to 
GnRH analogs with better antitumor activity. This would provide an added benefit for application in hormone-
dependent cancers and make the new agonist(s) also suitable for application in hormone-independent cancers of e.g. 
prostate and ovary. 
Three different types of carbohydrates: glucose, galactose and lactose, were attached to the N-terminus of the GnRH 
peptide analogs. C12 (2-Amino-D,L-dodecanoic acid) was conjugated either to the N-terminus of the glycopeptides 
(compounds 1-6) or incorporated into the middle of the sequence at position 7 in place of Leu (compounds 7-8). D-
Amino acid substitution at position 6 was performed to produce derivatives of triptorelin ([w6]GnRH). Glutamine 
(Gln) was used in place of glutamic acid (Glu) as the first amino acid in the GnRH sequence in compounds 1-8 for 
two reasons: firstly, it is known that endogenous GnRH (9) is produced with N-terminal glutamine which 
spontaneously cyclizes to form pyroglutamic acid, and secondly we have previously shown that GnRH conjugates 
with Gln have longer half-lives than those with Glu (Moradi et al., 2013). 
Constructs 1-8 were tested in vitro to assess their permeability through biological membranes and stability against 
enzymatic degradation. The compounds’ direct antiproliferative activity in human prostate and ovarian cancer cell 
lines and their toxicity to normal blood and pituitary cells was investigated along with their ability to stimulate the 
release of gonadotropins from pituitary cells. Additionally, the impact of sex steroids (dihydrotestosterone, DHT, or 
17ß-estradiol, E2) on the growth inhibitory effects of the GnRH analogs was studied. The lead compound (6) was 
selected from in vitro studies and, along with triptorelin (10) as a positive control, was tested in Swiss albino mice to 
investigate its ability to stimulate the release of LH after subcutaneous administration.  
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2. MATERIALS AND METHOD  
2.1. Design and synthesis 
2.1.1. Carbohydrate synthesis 
Acetylated, butanoic acid-conjugated carbohydrates were synthesized adapting or following published procedures 
(Varamini et al., 2012b) as summarized in Scheme 1, and 1H-NMR spectra matched the published ones (Moradi et 
al., 2013). Chemical structures are shown in Table 1. 
 
 
2.1.2. Peptide synthesis 
Peptides were assembled on Rink amide resin following the in situ neutralization protocol for Fmoc solid-phase 
chemistry.(Alewood et al., 1997) Briefly, Nα-Fmoc-protected amino acids (4.2eq.) were activated with 
HBTU/DIPEA (4eq./5eq.) and double coupled for at least 45 minutes each. The following side chain protecting groups 
were used: Arg(Pbf), Tyr(tBu), Ser(tBu), Trp(Boc), His(Trt), Gln(tBu). The Fmoc protecting group was removed by 
treatment with piperidine in DMF (1:5, 1 x 10 min, 1 x 20 min). The Dde-protected C12-lipoamino acid was 
synthesized following published procedures.(Gibbons et al., 1990; Ross et al., 2008) The Dde protecting group was 
removed by treatment with hydrazine hydrate in DMF (1:50, 3 x 5 min). Carbohydrate derivatives 13a-c (1.3eq.) were 
activated with HBTU/DIPEA (1.25eq./2eq.) and coupled overnight. The resin was washed with dimethylformamide, 
dichloromethane and methanol and treated with hydrazine hydrate/methanol (3:1, 2 x 30 min) to remove the acetyl 
protecting groups. The resin was washed thoroughly with methanol and dried under vacuum overnight. The peptide 
was cleaved by treatment with a mixture of TFA/water/tri-isopropylsilane (95:2.5:2.5) for 2 hours. Addition of cold 
diethyl ether precipitated the peptide, the peptide suspension was centrifuged and the supernatant discarded. The 
peptide pellet was washed with cold diethyl ether once and then dissolved in a mixture of acetonitrile and water 
containing 0.1% trifluoroacetic acid and lyophilized. 
2.1.3. Compound Purification 
Peptides were purified by reverse phase high performance liquid chromatography (RP-HPLC) on a Shimadzu system 
using a Vydac C18 column (5µm, 22 x 250 mm) running a gradient of two solvents, A: H2O, 0.1% TFA, and B: 
acetonitrile/H2O 9:1, 0.1% TFA. Either a gradient of 20% to 60% B over 60 minutes (peptides 1-3, 7, and 9-10) or a 
gradient of 10% to 60% B over 70 minutes (peptides 4-6 and 8) was used at a flow rate of 10 ml/min. Collected 
fractions were analyzed by High resolution MS and ESI-MS and analytical RP-HPLC using a Vydac C4 and C18 
column (5µm, 4.6 x 250mm) and a gradient of 0% to 100% B over 30 minutes at a flow rate of 1 ml/min. Pure 
fractions were combined and lyophilized. 
2.2. Characterization 
1. Glc-C12-[Q1]GnRH; HPLC retention time: C4 Vydac column (17.7/17.9 min), C18 Vydac column (18.5/18.7 min); 
HR-MS [M+2H]2+: calc.: 829.4385, found: 829.4421. 
2. Gal-C12-[Q1]GnRH. HPLC retention time: C4 Vydac column (17.0/17.4 min), C18 Vydac column (17.7/18.2 min); 
HR-MS [M+2H]2+: calc.: 829.4385, found: 829.4425. 
3. Lac-C12-[Q1]GnRH. HPLC retention time: C4 Vydac column (16.8/17.2 min), C18 Vydac column (17.5/17.9 min); 
HR-MS [M+2H]2+: calc.: 910.4649, found: 910.4691. 
4. Glc-C12-[Q1][w6]GnRH. HPLC retention time: C4 Vydac column (18.3/18.7 min), C18 Vydac column (18.9/19.1 
min); HR-MS [M+2H]2+: calc.: 893.9674, found: 893.9874. 
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5. Gal-C12-[Q1] [w6]GnRH. HPLC retention time: C4 Vydac column (18.9/19.3 min), C18 Vydac column (18.6/19.1 
min); HR-MS [M+2H]2+: calc.: 893.9674, found: 893.9712. 
6. Lac-C12-[Q1] [w6]GnRH. HPLC retention time: C4 Vydac column (18.0/18.4 min), C18 Vydac column (19.8/20.4 
min); HR-MS [M+2H]2+: calc.: 974.9938, found: 974.9981. 
7. Lac-[Q1][w6][C127]GnRH. HPLC retention time: C4 Vydac column (17.0/17.1 min), C18 Vydac column (18.0 
min); HR-MS [M+2H]2+: calc.: 918.4518, found: 918.4545. 
8. Lac-[Q1][C127]GnRH. HPLC retention time: C4 Vydac column (18.2/18.7 min), C18 Vydac column (19.1/19.8 
min); HR-MS [M+2H]2+: calc.: 853.9229, found: 853.9261. 
2.3. In vitro experiments 
2.3.1 Cell lines 
The Caco-2 human epithelial colorectal adenocarcinoma cell line was obtained from the American Type Culture 
Collection (ATCC, Rockville, USA). Different steroid hormone-dependent and independent, sex-specific human 
carcinoma cell lines were used. The LNCaP (GnRH receptor positive; androgen-sensitive prostate adenocarcinoma), 
PC3 and DU145 (GnRH receptor positive; androgen-independent human carcinoma), OVCAR-3 (GnRH receptor 
positive; estrogen, progesterone and androgen-receptor positive ovarian carcinoma) and SKOV-3 (GnRH receptor 
negative; estrogen-resistant ovarian carcinoma) human cell lines were purchased from ATCC and were provided by 
Professor Judith Clements at the Translational Research Institute and Queensland University of Technology, and 
Professor Rodney Minchin, School of Biomedical Sciences, The University of Queensland.  
The method for Caco-2 cell homogenate stability and membrane permeability is described in Supplementary 
Information 
2.3.2 Tumor cell proliferation assay (MTT assay) 
MTT cell proliferation assay was performed as previously described.(Moradi et al., 2015b) The cells were passaged 
and plated (90 μL/well) in flat-bottomed 96-well plates at 2 × 105 cells/mL for LNCaP, DU145 and OVCAR-3 or 1 
× 105 cells/mL for PC3 and SKOV-3 cells.  Compounds were used at a final concentration of 1, 10, 25, 50 or 100 µM 
in 0.5% DMSO in the culture media (n = 3/compound, in at least 3 independent experiments). 
2.3.3 Triptorelin competition assay 
LNCaP, DU145 and OVCAR-3 cells were pre-treated with 100 µM (100 µL) of triptorelin. After 2 h incubation, cells 
were washed and fresh media added at 90 µL. Compounds were added to each well (10 µL) at their effective 
concentration (50 µM) and incubated for 48 h followed by MTT assay. 
2.3.4 Steroid treatment studies 
After cells reached 70% confluence, they were washed twice with PBS and media that contained 10% charcoal 
stripped FBS (CSS) was added to the flask. Cells were either seeded in 96-well plates after 48 h incubation and treated 
with compounds 1-8 and controls at 50 µM to perform the MTT assay or were treated with fresh CSS media that 
contained 5 nM 17ß-estradiol (E2) or 50 nM dihydrotestosteron (DHT) for an additional 48 h incubation. Treated 
cells were plated in 96-well plates. Compounds were added at 50 µM. MTT assay was performed after 48 h incubation. 
2.3.5 Isolation of PBMCs 
This assay was completed following approval from the University of Queensland Ethics Committee (Ethics Approval 
Number: 2009000661). Blood samples (4 mL) were taken from a healthy adult volunteer and PBMCs were isolated 
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by Ficoll gradient centrifugation at 400 g for 30 min. Mononuclear cell layer was retained at the plasma-Ficoll 
interface and washed with RPMI 1640 (x3). Cells were resuspended in 10% FBS in RPMI and seeded at 1 × 106 
cells/mL (80 µL) in 96-well flat bottom plates. Phytohemagglutinin (10 µg/mL) was added to activate the cells. After 
1 h incubation at 37 °C in a 5% CO2 atmosphere, compounds 1-10 in 5% DMSO in PBS were added (10 L/well) at 
50 and 100 µM. The MTT assay was performed after 48 h incubation as above. 
2.3.6 In vitro LH and FSH release assays 
2.3.6.1 Rat pituitary cell preparation 
Pituitary cells were isolated and cultured according to a previously published method.(Moradi et al., 2015b) Cells 
were plated at 4 × 105 cells/mL in 96-well plates at a density of 3 × 104 cells/well and incubated for 72 h at 37 ºC.  
2.3.6.2 LH and FSH release assay  
Pituitary cell dispersion was performed as described elsewhere.(Moradi et al., 2015a) Briefly, plated pituitary cells 
were centrifuged at 400 g for 10 min. Cells were washed and replaced by challenge media, which contained 0.1% 
bovine serum albumin in DMEM. GnRH derivatives 1-8 and control peptides (GnRH and triptorelin) were then added 
at 0.5, 5 or 50 nM (10 µL). The treated pituitary cells were incubated at 37 ºC for 2 h. The level of LH and FSH was 
quantified according to the manufacturer’s instructions using a commercial enzyme-linked immunosorbent assay 
(ELISA) kit (USCN Life Science Inc., Wuhan, China). 
 
2.4. In vivo experiments 
2.4.1 Animals and compounds’ administration 
Male Swiss Albino mice (6-8 weeks of age, weighing 34-45 g at the time of assessment) were purchased from The 
University of Queensland biological resources breeding facility. Mice were housed five per cage in an artificially lit 
room on a 12 h light/12 h dark cycle at controlled temperature (22.2 ± 0.2 °C; mean ± StDev) and humidity (51–65%) 
with food and water available ad libitum. The animal experimentation protocols were approved by The University of 
Queensland Animal Ethics Committee (AEC#SCMB/005/11/ARC) and performed according to NHMRC animal 
handling guidelines.  
Prior to start of the experiments, mice were allowed to acclimatize to the new environment for two weeks to minimize 
stress and thus experimental variation. During this period, mice were trained every alternative day by mimicking 
experimental manipulation procedures.  
Each mouse was administered 50 µmol of compounds 6, triptorelin or vehicle (10% DMSO) subcutaneously (50 µL). 
Just prior to administering the compounds, a single tail tip blood sample was collected to establish baseline, adhering 
to guidelines established previously (Steyn et al., 2013). Post administration, 2 µL of blood was collected at 30-minute 
intervals for duration of 6 hours. Collected blood was diluted in 58 µL of PBS-T and immediately stored in dry ice. 
Samples were kept at -80 °C prior to batch analysis using a validated ultra-sensitive mouse LH ELISA method (Steyn 
et al., 2013). 
2.4.2 Assessment of in vivo LH secretion 
A sensitive sandwich ELISA was used to measure serum concentration of LH, strictly adhering to published 
methodology (Steyn et al., 2013). Briefly, a monoclonal antibody (50 µL anti-bovine LH beta subunit, University of 
California) was used to coat 96-well high-affinity binding microplates and incubated overnight at 4°C. Using a 2-fold 
serial dilution of mouse LH in 0.2% (w/v) BSA-1×PBS-T (PBS with 0.05% Tween 20), a standard curve was 
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generated (0.00195 to 4 ng/mL). Wells were incubated with 200 µL of blocking buffer (5% skim milk in PBS-T) for 
2 h at room temperature (RT). Detection antibody (polyclonal antibody, rabbit LH antiserum, 50 µL) along with the 
LH standards and plasma samples were incubated for 1.5 h at a final dilution of 1:10000 at RT. This step was followed 
by the addition of 50 µL horseradish peroxidase-conjugated antibody (polyclonal goat anti-rabbit antibody) at a final 
dilution of 1:2000 and 1.5 h incubation at RT. O-phenylenediamine substrate (containing 0.1% H2O2) was added to 
each well and left at RT for 30 minutes. Hydrochloric acid at 3 M concentration was used to stop the reaction. The 
absorbance of each well was read at a wavelength of 490 nm (Sunrise; Tecan Group). OD values of unknowns were 
interpolated against a nonlinear regression of the LH standard curve and from there the LH concentrations were 
determined in the whole blood samples. LH secretory responses were also expressed as the area under the curve 
(AUC). The within and between assay coefficient of variation of LH assays were below 5%. 
2.4.3 Assessment of in vivo LH secretion 
A sensitive sandwich ELISA was used to measure serum concentration of LH, strictly adhering to published 
methodology (Steyn et al., 2013). Briefly, a monoclonal antibody (50 µL anti-bovine LH beta subunit, University of 
California) was used to coat 96-well high-affinity binding microplates and incubated overnight at 4°C. Using a 2-fold 
serial dilution of mouse LH in 0.2% (w/v) BSA-1×PBS-T (PBS with 0.05% Tween 20), a standard curve was 
generated (0.00195 to 4 ng/mL). Wells were incubated with 200 µL of blocking buffer (5% skim milk in PBS-T) for 
2 h at room temperature (RT). Detection antibody (polyclonal antibody, rabbit LH antiserum, 50 µL) along with the 
LH standards and plasma samples were incubated for 1.5 h at a final dilution of 1:10000 at RT. This step was followed 
by the addition of 50 µL horseradish peroxidase-conjugated antibody (polyclonal goat anti-rabbit antibody) at a final 
dilution of 1:2000 and 1.5 h incubation at RT. O-phenylenediamine substrate (containing 0.1% H2O2) was added to 
each well and left at RT for 30 minutes. Hydrochloric acid at 3 M concentration was used to stop the reaction. The 
absorbance of each well was read at a wavelength of 490 nm (Sunrise; Tecan Group). OD values of unknowns were 
interpolated against a nonlinear regression of the LH standard curve and from there the LH concentrations were 
determined in the whole blood samples. LH secretory responses were also expressed as the area under the curve 
(AUC). The within and between assay coefficient of variation of LH assays were below 5%. 
2.5. Statistical analysis 
Data are presented as means ± StDev. Differences between groups were identified by a one-way ANOVA followed 
by Dunnett’s post-hoc test and comparison with the corresponding control group. All measures were performed using 
GraphPad Prism (version 6.0; Graph-Pad Software Inc.). The threshold level for statistical significance was set at 
P<0.05. 
3. RESULTS AND DISCUSSION 
We developed GnRH analogs that were more stable and potent than the currently available agonists. Improve stability 
of the GnRH peptide will increase its duration of activity, consequently reducing its dosing frequency. 
The current GnRH analogs in clinical use achieve the desired pharmacological effect by primarily acting on the 
pituitary with less direct antiproliferative effects on tumor cells. We hypothesized that increasing the stability and 
potency of the GnRH agonists through conjugation of a lipid chain and carbohydrates might increase their direct 
antiproliferative activity (Hollosy et al., 2002). This would result in analogs with dual action in hormone-dependent 
cancers, both blocking the release of sex hormones and directly inhibiting the growth of the tumor. If the antitumor 
activity is strong, they can also be used in hormone-independent reproductive cancers.  
 3.1. Design and synthesis of GnRH and its derivatives 
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The native GnRH (9), triptorelin (10) and their glycolipid analogs 1-8 were synthesized, purified to a single peak (> 
95% purity) by analytical RP-HPLC and characterized using high resolution mass spectrometry (HR-MS). All 
chemical structures and compounds’ characterizations including HPLC and HR-MS figures are reported in the 
Supplementary Information (Table S1 and Figure S1). Modifications included the conjugation of lipid and 
carbohydrate moieties in GnRH-based analogs at position 1 (compounds 1-3) or position 7 (compound 7). Same 
modifications at position 1 and 6 were performed using a D-Trp6-substituted peptide (triptorelin) yielding three 
triptorelin or [w6]GnRH-based compounds (4-6 and 8). The amino acid sequences are shown in Table 2. 
3.2. In vitro experiments 
3.2.1. Caco-2 cell homogenate stability and membrane permeability assay 
The conventional colorectal adenocarcinoma (Caco-2) cell homogenate assay was used to determine the effect of 
lipid and sugar conjugation on the stability of GnRH peptide in vitro. We applied lipidation and glycosylation 
techniques with a history of improving stability and membrane permeability to produce more effective GnRH analogs 
(Varamini et al., 2012a, b). The native GnRH peptide (9) had a half-life of around 10 min after incubation with Caco-
2 cell homogenates (Table 3). The combination of lipidation and glycosylation caused a 4–6-fold increase (39.8–61.3 
min) in the metabolic stability of the native peptide (9) regardless of the position of the lipid in the sequence. The 
same modification strategies in compounds with D-Trp at position 6 ([w6]GnRH-based derivatives) and the lipid 
moiety at the N-terminus (4–6) significantly increased the half-life of the parent peptide (10) by 5.5–6.5-fold (p<0.05). 
Among all different carbohydrates used, lactose produced the most stable analogs in both GnRH- or [w6]GnRH-based 
derivatives. The stability of GnRH glycolipid that bore the lipid modification in the middle of the sequence (7) was 
not further increased by D-Trp6 substitution (8). The findings of the Caco-2 cell stability assay suggested that the best 
modification strategy was N-terminal lipid and sugar conjugation in [w6]GnRH-based derivatives (4–6).  
 
Although the pituitary gland sits outside the blood-brain barrier (Nussey and Whitehead, 2001), the GnRH agonist 
needs to cross cell membranes to reach blood circulation if administered via any route other than intravenous injection. 
Peptide analogs with a higher apparent permeability are shown to have better absorption and produce higher plasma 
peak concentrations compared to those with lower membrane permeability (Varamini et al., 2012b). A Caco-2 cell 
membrane model was used as a preliminary tool to screen membrane permeability. Propranolol was used as a positive 
control because it was completely absorbed by the gastrointestinal tract (GI)(Johnsson and Regardh, 1976). For 
propranolol, Papp was obtained at 0.8 and 1.3 × 10-5 cm/s in the first and second experiment, respectively. Mannitol 
was used in this experiment as a negative control due to very low absorption in the GI. The parent peptide, GnRH (9), 
displayed a low Papp of 1.2 × 10-7 cm/s. With a slight improvement, the permeability of triptorelin (10) was found to 
be 2.8 × 10-7 cm/s. However, conjugation of a lactose moiety to the peptides with N-terminal lipid, resulted in a 
significant increase in the apparent permeability of the peptides. Thus, compounds 3 and 6 (Papp of 32.8 and 19.2 × 
10-7 cm/s, respectively) showed highest apparent permeability, when compared to GnRH, [w6]GnRH and even the 
lactose-modified peptides with the lipid in the middle of the sequence, i.e. 7 and 8 (p< 0.05, Table 3).  
These findings were in line with our previous report where the lactose group alone was shown to be the most effective 
carbohydrate moiety in improving the absorption of GnRH peptide through biological membranes (Moradi et al., 
2014). It caused an unprecedented 700-fold increase in membrane permeability of a different peptide (Varamini et 
al., 2012b). 
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3.2.2. Tumor cell proliferation assay (MTT assay) 
GnRH pathways have been shown to be involved in cell growth, invasion and angiogenesis of peripheral tumors, to 
varying extent (Skinner et al., 2009). GnRH receptor ligands have been shown to act differently on the GnRH receptor 
positive peripheral tissues at different doses (Mezo and Manea, 2010); a dose-dependent increase in cell proliferation 
at low (nanomolar) concentrations and inhibitory action at higher (micromolar) concentrations (Chen et al., 2007). 
This has been explained by the differential expression profiles of GnRH receptors (Mezo and Manea, 2010). 
Therefore, in this study tumor cell lines with a variety of GnRH receptor expression levels and hormone dependence 
were used to investigate this effect of the GnRH glycolipids. Cell proliferation was evaluated by assessing the 
mitochondrial reduction of MTT in three GnRH-receptor positive prostate cancer cell lines (LNCaP, DU145 and PC3) 
and ovarian cancer cell lines with (OVCAR-3) and without (SKOV-3) the GnRH-receptor. 
- Prostate cancer cell lines: All analogs 1-8 inhibited the growth of hormone DU145 cells after 48 h incubation with 
IC50 values between 36–62 µM (Table 4). The most potent analogs were [w6]GnRH-based derivatives that bore a 
sugar and lipid at their N-terminus (4, 5 and 6) with IC50 values obtained at 39.4, 37.4 and 36.4 µM, respectively 
(p<0.05). Compounds 4-6 were ~1.7 times more potent than triptorelin, indicating that sugar and lipid modification 
could improve their direct antitumor activity. This finding is of particular importance for treating prostate cancers that 
progress to hormone-refractory state. Although compound 8 had the same sugar (lactose) and D-Trp modification as 
compound 6, replacement of Leu with C12 at position 7 reduced its activity against DU145 cells by about 50%. GnRH 
peptide did not affect the growth of DU145 cell line (IC50 >100 µM). A similar pattern, albeit with slightly higher 
IC50 values, was obtained when the other GnRH receptor positive prostate cancer cell line, LNCaP. Analogs 5 and 6 
produced a significant inhibitory effect on the growth of LNCaP prostate cancer cells (IC50 values at 57.6 µM for 
analog 5 and 52.2 µM for analog 6). This effect was higher than that of triptorelin (p<0.05, Table 4). The above 
finding suggested that N-terminal lipid and sugar modification, regardless of the type of sugar, produced the most 
potent analogs against DU145 and LNCaP cell lines with direct growth inhibitory activity. It has previously been 
reported that the position of a bulky residue on the N-terminus of the GnRH backbone enhanced the conformational 
stability of the peptide and forced the formation of a β-II turn for greater receptor binding. This in turn enhanced 
GnRH receptor-mediated antiproliferative activity.(Pfleger et al., 2002) It is plausible the position of bulky 
carbohydrate and lipoamino acid residues on the N-terminus of the GnRH backbone contributed to the enhanced the 
antitumor and gonadotropin release activity of GnRH glycolipids. The growth of PC3 cells was not significantly 
inhibited by any of the analogs 1-8 or controls 9-10 (Table 4). This finding was in line with a previous report where 
PC3 cell growth was not inhibited by triptorelin, though triptorelin significantly inhibited the growth of LNCaP cells 
(Ravenna et al., 2000). 
- Ovarian cancer cell lines: The growth of OVCAR-3 cells was affected to a variable extent after being treated by 
different glycolipopeptides. GnRH-based derivatives, 1 and 2, with a glucose or galactose moiety produced the highest 
antiproliferative activity with IC50 values at 41.8 and 46.3 µM, respectively. Nevertheless, lactose-modified GnRH-
based compounds 3 and 7 did not exert any effects on these cells. Analogs 4-6 in the [w6]GnRH-based group of 
compounds significantly inhibited the growth of OVCAR-3 cells (IC50: 60–65 µM) while compound 8 in the same 
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group did not produce any significant effect. The absence of growth inhibitory effects by compounds 7 and 8 against 
the OVCAR-3 cell line can be explained by the mid-sequence lipid position. It is possible that mid-sequence lipid 
modification renders the compounds unable to activate the relevant signaling pathway and eventually to inhibit the 
cell growth.  
 
No significant growth inhibition was observed when the GnRH-receptor negative SKOV-3 cells were treated with 
compounds 1-10 (Table 4). 
 
 
3.2.3. Effect of GnRH glycolipids on normal peripheral blood mononuclear cells (PBMCs) and rat pituitary cells 
PBMCs as a model of non-cancerous human cells and rat pituitary cells were used to determine the toxicity of 
compounds 1-8. MTT assay was also used to determine the effect of the GnRH derivatives on the proliferation of 
non-cancerous cells: human PBMCs and isolated rat pituitary cells. No adverse effects were observed in the growth 
of pituitary cells or PBMCs cells after being treated with the two highest concentrations of the GnRH derivatives 1-
8 . (Figure 1, p>0.05), suggesting that the growth inhibitory effect was selective for cells that overexpressed the 
GnRH-receptor.  
3.2.4. Triptorelin competition studies: GnRH receptor-mediated antiproliferative activity 
In order to investigate whether the antiproliferative activity of glycolipopeptides was mediated through GnRH 
receptors, a competitive binding study was performed in DU145, LNCaP and OVCAR-3 cell lines. The effect of all 
compounds with significant growth inhibitory activity (at 50 µM) was antagonized after 2 h pretreatment with the 
100 µM triptorelin (p<0.05, Figure 3a-c. Agonist pretreatment did not affect the activity of analogs with low 
antiproliferative activity on these cell lines (analogs 2-3 and 7-8 in LNCaP and compounds 3 and 7-8 in OVCAR-3 
cells). These results suggest a selective receptor-mediated action of the sugar- and lipid-modified GnRH analogs in 
receptor-positive cell lines. It has previously been reported that the receptor-mediated antiproliferative activity of 
GnRH analogs occurred by inhibiting the mitogenic signal transduction pathways of the epidermal growth factor 
receptor in prostate, endometrial, ovarian, and breast cancer cell lines.(Grundker et al., 2000) This could explain the 
antiproliferative effect of GnRH analogs on GnRH-R positive cell lines (LNCaP, OVCAR-3 and DU-145) and not on 
GnRH receptor negative cells (SKOV-3). 
3.2.5. Impact of sex steroids on the antiproliferative activity 
Steroid hormones were previously shown to have regulatory functions on the growth inhibitory effect of GnRH 
agonists and the expression level of GnRH receptors, regardless of cells being hormone-dependent or not (Kang et 
al., 2001; Leuschner et al., 2003). Herein, we studied the correlation between the antiproliferative activity of 
glycolipopeptides and steroids in a steroid-depleted media (CSS). The antiproliferative effect of GnRH glycolipids 
(50 µM) was investigated in the presence or absence of DHT and E2 in DU145 and OVCAR-3 cells, respectively. 
The sensitivity of DU145 cells to the growth inhibitory effect of compounds 1-10 was significantly reduced (30-41%, 
p<0.05) when cultured in steroid-depleted media (CSS). However, after reconstitution of the media with DHT, the 
antiproliferative activity of the compounds was restored (Figure 2a). These results were consistent with previous 
reports that showed a steroid-dependent antiproliferative activity of GnRH agonists.(Leuschner et al., 2003) In this 
study, Leuschner et al. reported that DHT-dependent upregulation of GnRH receptor expression (up to 119%) in 
GnRH receptor positive prostate cancer cells was responsible for this hypersensitivity (Angelucci et al., 2009). 
Receptor upregulation was observed to the same extent when cells were treated with a GnRH agonist and DHT 
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(Angelucci et al., 2009). The higher sensitivity of DU145 cells to glycolipopeptides and triptorelin is plausibly due to 
the increased number of GnRH receptors in the presence of DHT. 
In contrast to DU145 cells, the antiproliferative effects of compounds on OVCAR-3 cells was either unaffected (1-5 
and 9-10) or increased (6-8) in CSS media. However, the reconstitution of the media with E2 significantly decreased 
the sensitivity of the OVCAR-3 cells to all compounds 1-10 compared to the CSS media. (Figure 2b). It has been 
previously shown that estrogen functions as a mitogen in OVCAR-3 cells, which can neutralize the growth inhibitory 
effect of GnRH-based compounds (Kang et al., 2001). This observation was consistent with a previous study where 
pre- or co-treatment with E2 significantly attenuated the growth inhibitory effect of a GnRH agonist. In this report, a 
down-regulation of GnRH receptor mRNA was observed, which could explain the attenuation of growth inhibition 
after treatment with 17ß-estradiol (Kang et al., 2001). 
3.2.6. In vitro LH and FSH release study 
Gonadotropin release was studied using rat anterior pituitary cells in primary culture after 2 h incubation with the 
analogs (Figure 4a). Compounds 5 and 6 increased the level of FSH up to 1.8 times from dispersed pituitary cells 
compared to the negative control (up to 2 ng/mL for compound 6 compared to 1.1 ng/mL for PBS, p>0.05). GnRH 
(9) and triptorelin (10) also stimulated the FSH release significantly up to 1.8 and 2.3 ng/mL, respectively (p>0.05). 
The level of LH release was significantly increased by most of the glycolipopeptides (1, 3-6 and 8, Figure 4b, p<0.05). 
However, the stimulatory effects of [w6]GnRH-based compounds 4-6 with the N-terminal lipid were higher than other 
analogs (2.5 to 3.8 times relative to PBS control). Compounds 5 and 6 were effective in stimulating the LH secretion 
level in culture at all three concentrations (up to 173 ng/mL for compound 6 compared to 47 ng/mL for the negative 
control, p<0.05). The effect of compound 6 at 50 nM was even higher than triptorelin and GnRH at the same 
concentration (p<0.05). The higher efficacy of [w6]GnRH-based glycolipids (4-6) could be due to their higher 
stability, allowing them to stay intact for longer after binding to receptors on the pituitary.  
3.3. In vivo experiment: Efficacy studies for the release of LH in mice 
Analog 6 showed the most promising results in the in vitro studies. Thus, it was selected as the lead compound for 
further testing in mice. A preclinical method was developed in Swiss Albino mice in the context of our objectives. 
This mouse model was particularly valuable because: (1) the human GnRH receptor is homologous to the mouse 
receptor (Millar et al., 2004); (2) GnRH receptor agonism was determined by measuring the level of LH after acute 
administration and over a course of 6 hours post-injection; (3) frequent sampling allowed discrimination of the natural 
pulsatile effect on the release of LH from the effect of the compounds. Although it is critically important, the majority 
of studies that aim to develop new GnRH analogs do not consider endogenous LH release patterning; (4) a robust 
sensitive methodology that has been developed by Steyn et al. (Steyn et al., 2013) was used for the first time to 
measure the level of LH release to determine the efficacy of GnRH receptor ligands. Altogether this methodology 
provided a distinctive approach to gain insight into the agonist/antagonist efficacy of GnRH receptor ligands over a 
course of six hours post-treatment.  
LH release was measured every 30 min, over 6 h after SC administration of compounds 6, triptorelin (as a positive 
control) and PBS as the negative control. Plasma LH level rose gradually after administration of both analog 6 and 
triptorelin, with a peak response for triptorelin at 2.5 h (1.4 ng/mL). However, the LH level continued to rise after 
administration of compound 6 beyond the peak level observed for triptorelin giving an LH concentration of 1.7 ng/mL 
after 6 h of treatment (Figure 5a). These results indicated that compound 6 had a long-lasting effect with a higher 
maximum plasma level and hence, a better potency than triptorelin (due to the stronger stimulation of LH release at 
the same dose). In contrast to compound 6, the effect of triptorelin started to decline after 2.5 h 
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The area under curves (AUC) of LH release was obtained over 6 h indicating the duration of action of the compounds. 
A significant increase from 0.3 to 2.7 ng/mL/6h was observed in mice treated with glycolipopeptide 6 compared to 
the PBS group (Figure 5b, p<0.05). The AUC (duration of action) of LH released by mice treated with triptorelin was 
measured at 1.3 ng/mL/6h, which was significantly less than triptorelin (p<0.05). The in vivo studies suggest that 
compound 6 showed an improved potency and duration of action compared to triptorelin. 
 
 
 CONCLUSION 
 GnRH agonist therapy is a powerful therapeutic approach for the treatment of many conditions in reproductive 
medicine, particularly hormone-dependent tumors (e.g., prostate, breast, endometrial, and ovarian cancers). By 
exerting a direct and selective antiproliferative activity through GnRH receptor in overexpressing tumor cell lines, 
[w6]GnRH-based glycolypopeptides (4-6) offer great promises for the discovery of new GnRH therapeutics that are 
effective in hormone-independent prostate cancer. In particular, glycolipopeptide 6 showed the highest in vitro 
metabolic stability, direct antiproliferative activity, LH release efficacy in pituitary cells, and potent and long-acting 
gonadotropin releasing function. Compound 6 was superior to triptorelin in all in vitro and in vivo examinations, 
making it a promising candidate for the development of new GnRH agonists to treat hormone sensitive and refractory 
prostate cancer. 
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FIGURES 
 
Figure 1. Toxicity of glycolipopeptides 1-8 in (a) PBMCs and (b) isolated rat pituitary cells, as a percentage of cells 
treated with PBS (mean ± StDev, performed in three independent experiments, each in triplicate) after 48 h incubation. 
Statistical analysis was performed using a one-way ANOVA followed by Dunnett’s post-hoc test and comparison 
with the DMSO-negative control group. 
 
 
Figure 2. Effect of the reconstitution of the cell growth media with DHT and E2 on the sensitivity of (a) DU145 and 
(b) OVCAR-3 cells. Cells were grown in steroid free (CSS) media for 48 h then E2 (5 nM) or DHT (50 nM) was 
added to the media and incubated for 48 h. Treatment was commenced using glycolipid-modified GnRH analogs at 
50 µM. * p<0.05 experiments performed in normal media vs. CSS media. # p<0.05 experiments performed in steroid 
reconstituted media vs. CSS media. 
a b 
a b 
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Figure 3. Receptor-mediated antiproliferation in (a) DU145, (b) LNCaP, and (c) OVCAR-3 cells. Cells were 
pretreated with 100 µM triptorelin for 2 h and then the supernatant was replaced with compounds 1-8 and control 
peptides in fresh media at 50 µM. MTT assay was performed after 48 h (mean ± StDev, performed in three 
independent experiments, each in triplicate). Statistical analysis was performed using a one-way ANOVA (* p<0.05; 
**, p< 0.01, *** p< 0.001, difference between pretreated and untreated groups). 
 
a
 
b
 
c
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Figure 4. Effect of GnRH derivatives on the release of (a) FSH and (b) LH from rat pituitary cells. Statistical analysis 
was performed using a one-way ANOVA followed by the Dunnett’s post hoc test (* p<0.05; **, p< 0.01, *** p< 
0.001, increase in the FSH and LH level when compared to the PBS (negative control group). 
 
 
Figure 5. Efficacy of the lead compound 6 on the release of LH after subcutaneous administration in mice. (a) Plasma 
LH levels during the first 6 h post treatment and (b) the measured AUC over the 6 h sampling period following 
administration of glycolipopeptide 6, triptorelin (or [w6]GnRH, 50 µmol/mouse), or PBS (Mean ± StDev (n=5)). 
Statistical analysis was performed using a one-way ANOVA followed by the Dunnett’s post hoc test. *** p<0.001 
when compounds 6 and triptorelin were compared to PBS group (negative control) and # p<0.05 when compound 6 
was compared with triptorelin. 
a
 
b
 
b
 
a
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Scheme 1. Reaction conditions. (i) LiClO4, acetic anhydride, 40 °C, overnight; (ii) HBr (32%), AcOH, RT, 3 h; (iii) 
NaN3, NBu4HSO4, NaHCO3 (saturated), DCM, RT, overnight; (iv) NaN3, acetone, water, RT, overnight; (v) DCM, 
H-cube, flow 2 mL/min, pH2 40 bar, 35 °C, 1 h; (vi) succinic anhydride, pyridine, DMAP, DCM, 4 °C to RT, 
overnight. 
 
Table 1. Chemical structures of the synthesized carbohydrate derivatives. 
 
 
 
 
 
 
 
Table 2. Composition of GnRH derivatives 1-8. 
Compound Amino acid sequence 
1 Glc C12 Gln His Trp Ser Tyr Gly Leu Arg Pro Gly 
2 Gal C12 Gln His Trp Ser Tyr Gly Leu Arg Pro Gly 
3 Lac C12 Gln His Trp Ser Tyr Gly Leu Arg Pro Gly 
4 Glc C12 Gln His Trp Ser Tyr D-Trp Leu Arg Pro Gly 
5 Gal C12 Gln His Trp Ser Tyr D -Trp Leu Arg Pro Gly 
6 Lac C12 Gln His Trp Ser Tyr D -Trp Leu Arg Pro Gly 
7 - Lac Gln His Trp Ser Tyr Gly C12 Arg Pro Gly 
8 - Lac Gln His Trp Ser Tyr D -Trp C12 Arg Pro Gly 
9  
(GnRH) 
- - pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly 
10 
([w6]GnRH 
/triptorelin) 
  pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly 
Glc: glucose; Gal: galactose, Lac: lactose; C12: 2-amino-D,L-dodecanoic acid. 
  
 Glucose Galactose Lactose 
 11a 12a, 13a 11b 12b, 13b 11c 12c, 13c 
R1 OH OAc H H 
  
R2 H H OH OAc H H 
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Table 3. Caco-2 cell homogenate stability (t1/2) and Caco-2 cell membrane permeability (Papp) of GnRH glycolipids 
(1-8) and controls (9, 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aThe apparent permeability (Papp, cm/s) through Caco-2 cell monolayers. The data were quantified by LC/MS and each point is 
expressed as mean ± StDev (n = 4 from three independent experiments). Statistical analysis was performed using a one-way 
ANOVA followed by Dunnett’s post-hoc test and values compared with GnRH (* p < 0.05). 
[b]The values for compounds 7 and 8 were obtained from a different experiment for both stability and membrane permeability 
along with their corresponding controls (GnRH and [w6]GnRH). 
  
Compound t1/2 (min, Caco-2) 
Papp (×10-7, cm/s) 
[a]
 
1 42.1 ± 4.1 8.5 ± 3.97 
2 45.5 ± 3.1 1.4 ± 0.8 
3 61.3 ± 5.2 * 32.8 ± 2.4* 
4 109.7 ± 6.5 6.2 ± 0.33 
5 106.5 ± 4.8* 8.8 ± 1.6  
6 124.1 ± 4.1* 19.2 ± 1.1* 
GnRH (9) 10.2 ± 4.1  1.2 ± 0.31 
[w6]GnRH (10) 19.8 ± 2.8  2.8 ± 0.50 
Propranolol N/A 75.6 ± 15* 
Mannitol N/A 0.8 ± 0.2 
7 39.8 ± 3.0 * 6.8 ± 3.5[b] 
8 41.6 ± 3.2  8.9 ± 0.63 
GnRH (9) 13.3 ± 3.7 2.2 ± 0.94 
[w6]GnRH (10) 21.8 ± 1.9 9.9 ± 2.5 
Propranolol N/A 134 ± 8.1* 
Mannitol N/A 1.4 ± 0.03 
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Table 4. Antiproliferative activity of GnRH glycolipids in different cell lines. 
 
 
The IC50 values (µM) were estimated from concentration-response curves using nonlinear regression for inhibition of cell growth. 
Data are expressed as mean ± SD from at least three independent experiments, each in triplicate. Statistical analysis was performed 
using a two-way ANOVA (* p < 0.05, the IC50 for each compared with that of their corresponding parent peptide for the same 
cell line). 
 
GnRH 
Glycolipids 
1 2 3 4 5 6 7 8 
GnRH 
(9) 
[w6]GnRH 
(10) 
DU145 
IC50 (µM) 
57.4 ± 
3.1 
61.1 
± 2.9 
49.3 
± 2.3 
39.4 
± 
0.9* 
37.4 
± 
1.2* 
36.4 
± 
3.7* 
61.2 ± 
6.7 
62.1 ± 
2.8 
>100 62.1 ± 6.2 
LNCap 
IC50 (µM) 
83.1 ± 
4.3 
>100 >100 
69.3 
± 8.1 
57.6 
± 
3.4* 
52.2 
± 
3.1* 
>100 >100 >100 73.4 ± 6.3 
PC3 IC50 
(µM) 
>100 >100 >100 
91.2 
± 8.8 
83.5 
± 7.5 
89.7 
± 9.1 
>100 
92.4 ± 
8.2 
>100 98.1 ± 6.4 
OVCAR-3 
IC50 (µM) 
41.8 ± 
3.2* 
46.3 
± 
2.8* 
>100 
63.2 
± 5.5 
65.6 
± 5.6 
59.9 
± 7.1 
>100 
88.5 ± 
6.1 
90.1 ± 
3.4 
67.7 ± 4.4 
SKOV-3 
IC50 (µM) 
81.2 ± 
5.3 
88.4 
± 4.9 
>100 >100 >100 >100 >100 >100 >100 >100 
